Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SQM heads into the final week of August with a split story: the stock is up 6% on the week and 15% over the past month, yet options traders are the most defensive they have been all year.
The clearest tension sits in the options market. The put/call ratio has climbed to 1.23, more than two standard deviations above its 20-day average of 1.08 — a reading that puts it among the most defensive setups of the past 12 months, with only the 52-week high of 1.42 sitting above it. That shift has been rapid: the PCR was running below 1.02 for much of early August and has jumped sharply over the past two weeks, coinciding almost exactly with the stock's rally. Investors appear to be reaching for put protection as the price rises, rather than chasing upside.
Short positioning tells a much calmer story. Estimated short interest ticked down almost 6% on the week to roughly 2.4 million shares, and the borrow market is as relaxed as it gets. Cost to borrow has fallen more than 23% over the week to just 0.34%, and the lending pool is essentially unconstrained — availability relative to shares already borrowed is running at more than 9,000%, meaning there is no scarcity pressure whatsoever for would-be shorts. The short score has also drifted lower over the past fortnight, to 30.7 from around 31.2, consistent with a modest easing in short-side conviction. Nothing in the lending data supports a squeeze narrative.
The analyst community has been more active. Scotiabank raised its target to $104 from $93 this week — its second revision of the summer, after briefly cutting the target to $93 in late July before reversing. That $104 target sits well above the consensus mean of $85.58, which itself implies roughly 8% upside to Tuesday's close of $79.21. Goldman Sachs moved its target to $82 from $64 in mid-July while holding Neutral, and JP Morgan is at $100 with Overweight. The outlier on the other side is BofA, which carries an Underperform with a $53 target — the only firm below the current price. The bull case centres on expected 10% lithium volume growth this year, plus expansion projects in Australia and China. Bears point to structural oversupply risk in the lithium carbonate market, potential regulatory friction in Chile, and what they see as thin margins relative to the current valuation. At a trailing P/E near 10.9 and EV/EBITDA of 6.75, SQM is not obviously expensive for a specialty chemicals producer; the dividend score ranks in the 98th percentile, and the 90-day EPS momentum factor ranks at 84.
The ownership structure anchors the stock in a way that limits short-side optionality. Inversiones SQYA holds 24.6% and Tianqi Lithium another 22.2%, together accounting for nearly half the share count. Tianqi's position has been unchanged since September 2025, after a cluster of sales at prices around $88-95 back in mid-2022. The most recent institutional moves are incremental: BlackRock added a small position in July, Vanguard edged slightly higher, while Van Eck trimmed modestly. No active manager is making a decisive directional bet.
Most recent earnings reaction data points to a stock that can move meaningfully around results. The August print saw a 5.3% next-day gain, and May's result generated a similar immediate pop before giving back ground over five days. The next scheduled event is not until mid-November, so near-term catalysts will depend on lithium spot price direction and any update on the Chilean Atacama concession framework. Closest peer ALB ended the week up just 0.4%, having dropped nearly 6% on Tuesday — a divergence worth watching as the two stocks typically track closely, with an 82% historical correlation.
What to watch next: whether the elevated put/call ratio resolves as a hedge that expires quietly into continued price strength, or whether it proves to have been anticipating a pullback toward the $75 level that marked resistance earlier this summer.
See the live data behind this article on ORTEX.
Open SQM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
